SEC chair backs “minimum effective dose” disclosure and targeted tokenization pilots

The U.S. Securities and Exchange Commission (SEC) is signaling support for streamlined “minimum effective dose” disclosure rules and tightly scoped equity‑tokenization pilots via an innovation exemption, according to new remarks from Chair Paul S. Atkins. The U.S. Securities and Exchange…